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Introduction: Glutamine (GLN) has been suggested to have a beneficial influence on outcomes of critically ill
patients. However, recent large-scale trials have suggested harm associated with GLN supplementation. Recently,
systematic reviews on the use of parenteral GLN have been published; however, less information is available on
the role of enteral GLN. Therefore, the aim of this systematic review was to study the effects of enteral GLN
supplementation in patients with critical illness.
Methods: We identified randomized controlled trials conducted from 1980 to 2014 with enterally administered
GLN in adult critically ill patients. Studies of parenteral GLN only or combined enteral-parenteral GLN were
excluded. The methodological quality of studies was scored, and trial data were statistically combined. We
examined a priori the treatment effects in subgroups of trials of burn and trauma patients.
Results: A total of 11 studies involving 1079 adult critically ill patients and enteral GLN supplementation were
identified. Enteral GLN supplementation was not associated with a reduction of hospital mortality (risk ratio [RR]
0.94, 95 % confidence interval [CI] 0.65–1.36; p =0.74), infectious complications (RR 0.93, 95 % CI 0.79–1.10; p =0.39)
or stay in the intensive care unit (weighted mean difference [WMD] −1.36 days, 95 % CI −5.51 to 2.78; p =0.52).
However, there was a significant reduction in hospital stay (WMD 4.73 days, 95 % CI −8.53 to −0.90; p =0.02). In the
subset of studies of patients with burns, enteral GLN supplementation was associated with significant reductions
in hospital mortality (RR 0.19, 95 % 0.06–0.67; p =0.010) and hospital stay (WMD −9.16, 95 % CI −15.06 to −3.26;
p =0.002). There was no effect in trauma patients.
Conclusions: Enteral GLN supplementation does not confer significant clinical benefit in critically ill patients, with
the exception of reduced hospital stay. There may be a significant benefit in patients with burns, but data are
sparse and larger randomized trials are warranted to confirm this effect.Introduction
Immune-modulating nutrients are considered to modu-
late inflammatory and oxidative stress responses and to
optimize the impaired (cellular) immune function [1].
Glutamine (GLN) is the most abundant free (non-essen-
tial) amino acid of the 20 amino acids in humans. No
deficiencies are likely to be present in healthy persons,
as GLN can be synthesized de novo. However, in cata-
bolic and stress states that are commonly present in crit-
ically ill, trauma and burn patients, low plasma levels of* Correspondence: dkh2@queensu.ca
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(http://creativecommons.org/publicdomain/zeGLN upon intensive care unit (ICU) admission have been
encountered, leading to the assumption that these levels
are too low for the actual medical condition and that GLN
should be considered conditionally deficient [2]. The
metabolic effects of GLN suggest a role in the inflamma-
tory and oxidative stress responses [3]. On the basis of the
association of low plasma GLN levels (<420 μmol/L) upon
ICU admission and increased hospital mortality, one study
group suggested that GLN supplementation in critically ill
patients could be essential [4].
Since then, many studies on parenteral and/or enteral
GLN supplementation in critically ill patients have been
performed, with the earliest of these published in 1997
[5]. The authors of several older systematic reviews andarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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combined with enteral nutrition (EN) and parenteral
nutrition (PN), is associated with reduced infectious
morbidity and improved recovery from critical illness
compared with standard nutrition [6–8].
Results of earlier meta-analyses were based mainly on
small, single-center studies. This led to the development
of international guidelines for the use of enteral GLN in
critically ill patients [9–11].
However, in the latest meta-analysis published by the
Cochrane Database of Systematic Reviews, signals for mor-
tality reduction were lost and only moderate- and low-level
evidence on reduction of morbidity was found, with high
risk of overall bias, suspected publication bias and moderate
to substantial heterogeneity within the included studies [12].
Most recently, two large, multicenter studies—the Re-
ducing Deaths Due to Oxidative Stress (REDOXS) and
MetaPlus trials—have shown no effects of GLN on infec-
tious morbidity; however, more importantly, increased
long-term mortality in critically ill patients in the GLN
supplementation arms was demonstrated [13, 14]. To-
gether, the results of these two studies challenge current
guidelines and recommendations for enteral and/or par-
enteral GLN in critically ill patients, as safety concerns
have been communicated [15].
An up-to-date review on parenteral use of GLN has
become available recently [16]; however, no systematic
analysis focused on enteral GLN supplementation in
critical illness has been performed over the last 6 years
[17]. Moreover, a similar dose of GLN or glutamine-
alanine dipeptide administered through the enteral versus
the parenteral route has smaller effects on plasma GLN
levels, possibly owing to splanchnic extraction [18]. Fur-
thermore, investigators in many trials on PN supplemented
with GLN (typically without GLN in the control product)
have studied patients not receiving EN. In contrast, in the
control groups in the EN GLN studies, the standard com-
mercially available EN typically contains limited amounts
of GLN (5–6 g/L). Therefore, available data on parenteral
GLN supplementation cannot be extrapolated to EN sup-
plementation and thus may not be used as a basis for rec-
ommendations for enteral GLN administration.
In the present systematic literature review and meta-
analysis, we address the question whether enteral admin-
istration of GLN as part of nutrition support has a posi-
tive effect on clinical outcomes in general, trauma and
burn injury patients who were critically ill.
Methods
Study identification
The following databases were searched for articles
published between 1980 and September 2014: Embase,
MEDLINE, CINAHL, the Cochrane Central Register
of Controlled Trials and the Cochrane Database ofSystematic Reviews. In the literature search, we used
broad search terms containing “randomized,” “blind,”
“clinical trial,” “nutrition,” “nutritional support” or “dietary
supplementation” or “enteral nutrition” or “parenteral nu-
trition” or “parenteral nutrition solutions” and “critical
care” or “critical illness” or “intensive care unit”. The
results were then reviewed to identify articles describing
enteral GLN supplementation. A unique feature of this
meta-analysis is that no language restrictions were placed
on the searches. The authors personal files and refer-
ence lists of relevant review articles were also
reviewed. As this is a systematic review, no ethics board
approval or patient consent was required.
Study selection criteria
We included original studies only if they met the following
inclusion criteria:
1. Study design: randomized clinical trials.
2. Study population: critically ill adult patients
(>18 years of age), defined as patients admitted to
an ICU. When this information was unclear,
we considered a mortality rate higher than 5 %
(hospital mortality or, if this was not reported,
ICU mortality or 28-day mortality) in the control
group to be consistent with critical illness.
3. Intervention: enteral GLN versus control
(isonotrogenous control).
4. Study outcomes: must have included one
of the following: mortality, ICU and hospital
lengths of stay (LOSs) and infectious complications.
Studies in which the authors reported only other clinical
endpoints, such as duration of mechanical ventilation, and
studies of parenteral GLN only or combined enteral and
parenteral GLN were excluded.
Data abstraction
Decisions about the inclusion of the articles were made
in duplicate. Two reviewers, using a data abstraction
form with a scoring system, reviewed all original studies
independently. An assessment of the criteria for inclu-
sion, details on the patient population, intervention and
control and/or placebo, and clinical outcomes was done
as described in earlier publications [19]. Using a scoring
system we previously developed, we assessed the meth-
odological quality of individual trials according to (1)
whether randomization was concealed, (2) blinding, (3)
whether the analysis was based on the intention-to-treat
principle, (4) patient selection, (5) comparability of groups
at baseline, (6) extent of follow-up, (7) description of
treatment protocol and cointerventions and (8) definition
of clinical outcomes [19]. Each individual study was
scored from 1 to 14 (Table 1). Disagreement regarding the
Table 1 Study scoring data abstraction form used to score all original studies independently
Score
0 1 2
Randomization – Not concealed or not sure Concealed randomization
Analysis Other – Intention to treat
Blinding Not blinded Single-blind Double-blind
Patient selection Selected patients or unable to tell Consecutive eligible patients –
Comparability of groups at baseline No or not sure Yes –
Extent of follow-up <100 % 100 % –
Treatment protocol Poorly described Reproducibly described –
Cointerventions Not described Described but not equal or not sure Well described and all equal
Outcomes Not described Partially described Objectively defined
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consensus between the two reviewers. We attempted to
contact the authors of included studies and requested
additional information not contained in their published
articles.
Data synthesis
The primary outcome of the systematic review was
hospital mortality. From all studies, we extracted data
regarding hospital mortality if reported (specified or
assumed to be hospital mortality if not specified). If hos-
pital mortality was not reported, we used ICU mortality
or 28-day mortality. Secondary outcomes included infec-
tion and ICU and hospital LOSs. We used definitions of
infections as defined by the authors of the original arti-
cles. We combined data from all trials to estimate the
pooled risk ratio (RR) with 95 % confidence interval (CI)
for mortality and infectious complications and overall
weighted mean difference (WMD) with 95 % CI for LOS
data. Pooled RRs were calculated using the Mantel-
Haenszel test, and WMDs were estimated using theTable 2 Included randomized studies of enteral glutamine supplem
Author Year ICU population Settin
Houdijk et al. 1998 Critically ill trauma (100 %) Single
Jones et al. 1999 Mixed ICU (6 burns, 6 trauma) Single
Brantley and Pierce 2000 Critically ill trauma (100 %) Single
Hall et al. 2003 Mixed ICU (mostly trauma, 7 burn) Single
Garrel et al. 2003 Burns (TBSA: 20–80 %) Single
Zhou et al. 2003 Severe burns TBSA 50–80 % Single
Peng et al. 2004 Severe burns TBSA >30 % Single
Luo et al. 2008 Mixed ICU Medical-surgical Single
McQuiggan et al. 2008 Shock trauma patients Single
Pattanshetti et al. 2009 Burns (TBSA: 20–60 %) Single
van Zanten et al. 2014 Mixed ICU (109 trauma) Multic
GLN+ patients treated with glutamine supplemented enteral nutrition, GLN− patien
body surface areainverse variance approach. The random-effects model of
DerSimonian and Laird was used to estimate variances
for the Mantel-Haenszel and inverse variance estima-
tions [20]. All analyses except the test for asymmetry
were conducted using Review Manager (RevMan) 5.1
software [21].
When possible, studies were aggregated on an intention-
to-treat basis (Table 2). The presence of heterogeneity
was tested using a weighted Mantel-Haenszel χ2 test
and quantified by the I2 statistic as implemented in
RevMan 5.1 [21, 22]. Upon review of the dataset, we
found that one randomized controlled trial contained
other supplemental nutrients, not just GLN. To evaluate
the effect of that trial on the overall results, we performed
a sensitivity analysis wherein we excluded the trial to see
how it affected the overall results [14]. The possibility
of publication bias was assessed by generating funnel
plots and testing asymmetry of outcomes using methods
proposed by Rucker and colleagues [23]. We considered
p < 0.05 to be statistically significant and p < 0.20 as
the indicator of trend.entation in critically ill patients
g All patients GLN+ patients GLN− patients Reference
center 80 41 39 [24]
center 50 26 24 [25]
center 72 31 41 [26]
center 363 179 184 [27]
center 45 21 24 [28]
center 40 20 20 [29]
center 48 25 23 [30]
center 30 15 15 [31]
center 20 10 10 [32]
center 30 15 15 [33]
enter 301 152 149 [14]
ts treated with control enteral nutrition, ICU intensive care unit, TBSA total
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We performed a predefined subgroup analysis to assess
a number of possible influences on the effect of enteral
GLN supplementation on clinical outcomes. We first
explored whether there was a different treatment effect
of enteral GLN in patients with burn injury and patients
with trauma. The trial done by van Zanten and col-
leagues also contained an a priori subgroup analysis of
patients with trauma, and we were able to obtain the
data for the subset of trauma patients and include these
data in the subgroup analysis [14]. We also assessed the
effect of trial quality on outcome, as it is often hypothe-
sized that, compared with trials of higher methodo-
logical quality, trials of lower methodological quality
tend to yield more positive clinical signals for the therapy
being tested. Using our trial scoring tool, we designated
trials with a methodological score of 9 (out of a maximum
score of 14) or more (median of scoring of all trials) as a
high-quality trial for the purposes of this review.
Results
Study identification and selection
The literature search yielded 42 potentially eligible
randomized controlled trials, of which 11 with a total of
1079 patients were included in our systematic review
(see Table 2) [14, 24–33]. In total, 535 patients were
treated with GLN supplementation and 544 patients with
a control feed.
As shown in Table 3, a total of 33 studies [34–65] were
excluded for the following main reasons: (1) patients not
considered to be adult critically ill patients (n =9); (2) no
clinical outcomes meeting inclusion criteria (n =9); (3)
being duplicate studies, reviews of published trials or
subgroups of included studies (n =6); (4) crossover study
design (n =4); and/or (5) multiple other interventions
were studied, such as arginine, glycine, probiotics and
fibers (n =4).
Thus, we ultimately included 11 studies of enteral
GLN supplementation performed in ICU patients with
diagnoses ranging from trauma to burns and sepsis, as
described in Table 3 [14, 24–33]. The results were based
on data derived from the included studies, depicted in
Table 4.
Effect of enteral glutamine supplementation on hospital
mortality
When the data from 10 of the 11 total identified EN
GLN studies that reported on mortality (Fig. 1) were
aggregated, enteral GLN supplementation was not associ-
ated with a reduction in hospital mortality (RR 0.94, 95 %
CI 0.65–1.36; p =0.74; test for heterogeneity I2 = 21 %).
The combined hospital mortality was 79 (15.6 %) of 507
in the GLN group and 84 (16.3 %) of 515 in the control
group. In the sensitivity analysis without the van Zantenet al. trial [14], there was still no effect on mortality (RR
0.80, 95 % CI 0.46–1.38; p =0.42; heterogeneity I2 = 27 %).
Also, in the subgroup of trauma patients, no effect on
hospital mortality was found (RR 1.03, 95 % CI 0.54–1.97;
p =0.92; heterogeneity I2 = 0 %; n =5 studies). How-
ever, in the small subgroup of burn patients, a statistically
significant reduction in mortality (2 [3.6 %] of 56 versus
14 [23.7 %] of 59) was demonstrated (RR 0.19, 95 % CI
0.06–0.67; p =0.010; heterogeneity I2 = 0 %; n =3 studies).
Effect of glutamine supplementation on infectious
complications
When the four studies in which the researchers reported
infectious complications were aggregated, enteral GLN
supplementation was not associated with a reduction in
infectious complications (RR 0.93, 95 % CI 0.79–1.10,
p =0.39; heterogeneity I2 = 0 %) (Fig. 2). The overall
incidence of infection was 140 (36.3 %) of 386 in the
GLN group and 153 (39.2 %) of 390 in the control
group. A sensitivity analysis without the van Zanten et al.
study [14] showed a trend toward a reduction in infectious
morbidity (RR 0.83, 95 % CI 0.64–1.08, p =0.16; hetero-
geneity I2 = 0 %). Also, in the subgroup of trauma patients,
a trend toward a reduction in infectious morbidity
was found (RR 0.85, 95 % CI 0.68–1.06, p =0.15; het-
erogeneity I2 = 0 %; n =2 studies). In the small sub-
group of burn patients, few data on infections were
available. Zhou et al. [29] reported infections in 2
(10 %) of 20 of burn patients treated with GLN ver-
sus 6 (30 %) of 20 in the control group. Garrel et al.
[28] showed reductions in positive blood cultures in
7 (37 %) of 19 in GLN-treated patients versus 10 (45 %) of
22 in control subjects.
Effect of glutamine supplementation on ICU length of stay
When we aggregated data from the three studies in
which authors reported ICU LOS as mean ± standard
deviation (Fig. 3), we found that enteral GLN supple-
mentation was not associated with a reduction in
ICU LOS (WMD −1.36, 95 % CI −5.51 to 2.78; p =0.52;
heterogeneity I2 = 70 %). When we excluded the van
Zanten et al. study [14], we also observed no effect
on ICU LOS (WMD −1.59, 95 % CI −8.15 to 4.96; p =0.63;
heterogeneity I2 = 82 %). In the small subgroup of trauma
patients, we found a trend toward reduction in ICU LOS
(WMD −4.66, 95 % CI −9.68 to 0.36; p =0.07; hetero-
geneity I2 = 82 %; n =2 studies). In the small number
of trials with burn patients, no data on ICU LOS were
available.
Effect of glutamine supplementation on hospital length
of stay
When we aggregated the seven studies in which investi-
gators reported data on hospital LOS (Fig. 4), we found
Table 3 Excluded randomized studies of enteral glutamine supplementation in critically ill patients
Author Year Reasons for exclusion References
Jebb et al. 1995 Transplant and/or elective surgery patients [34]
Long et al. 1995 No clinical outcomes [35]
Jensen et al. 1996 No clinical outcomes [36]
Fish et al. 1997 Cancer patients [37]
Scolapio et al. 1997 Crossover design [38]
Anderson et al. 1998 Surgical patients [39]
Anderson et al. 1998 Pediatric cancer patients [40]
Den Hond et al. 1999 Not ICU patients [41]
Schloerb and Skikne 1999 Cancer and/or surgery patients [42]
Scolapio 1999 Crossover design [43]
Zhou et al. 1999 Earlier study of 2003 RCT already included [44]
Jackson et al. 2000 Surgery patients, no clinical outcomes [45]
Szkudlarek et al. 2000 Crossover design [46]
Chen et al. 2001 No clinical outcomes [47]
Scolapio et al. 2001 Crossover design [48]
Velasco et al. 2001 No clinical outcomes, duplicate of Houdijk et al. study [24] [49]
Boelens et al. 2002 No clinical outcomes [50]
Novak et al. 2002 Studies on critically ill patients were included in this review [51]
Flaring et al. 2003 Elective surgery patients [52]
García-de-Lorenzo et al. 2003 Systematic review, Individual studies were included in this review [53]
Boelens et al. 2004 Duplicate of Houdijk et al. study [24] [54]
Falcao de Arruda et al. 2004 Includes probiotics [55]
Peng et al. 2005 Duplicate study of earlier publication already [30] included [56]
Peng et al. 2006 Duplicate of a previous study [30] [57]
Guo et al. 2007 No clinical outcomes [58]
Kuhls et al. 2007 Too many interventions [59]
Spindler-Vesel et al. 2007 Too many interventions: RCT of GLN vs. fiber vs. peptide vs. fiber + synbiotics [60]
Beale et al. 2008 Non-isonitrogenous intervention including arginine and glycine [61]
Han et al. 2012 Elective surgery patients [62]
Cavalcante et al. 2012 No clinical outcomes, crossover design [63]
Han et al. 2014 No clinical outcomes [64]
Koksal et al. 2014 Only duration of mechanical ventilation reported [65]
GLN glutamine, ICU intensive care unit, RCT randomized controlled trial
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reduction in hospital LOS (WMD −4.73, 95 % CI −8.56
to −0.90; p =0.02; heterogeneity I2 = 52 %). The finding
of a significant reduction in hospital LOS persisted after
we excluded the van Zanten et al. study [14] (WMD
6.95 days, 95 % CI −12.37 to −1.53; p =0.01; heterogen-
eity I2 = 76 %). In the subgroup of trauma patients, no
reduction in hospital LOS was found (WMD −0.54,
95 % CI −4.40 to 3.31, p =0.78; heterogeneity I2 = 0 %;
n =4 studies). In the small subgroup of burn patients,
we found a significant reduction in hospital LOS
(WMD −9.16, 95 % CI −15.06 to −3.26; p =0.002; hetero-
geneity I2 = 52 %; n =3 studies).Effect of study quality on outcomes
There was no effect of enteral GLN on reduction in hos-
pital mortality in high-quality trials (RR 0.90, 95 % CI 0.55–
1.48; p =0.69) compared with low-quality trials (RR 0.84,
95 % CI 0.28–2.50; p =0.75) when we tested for subgroup
differences (p =0.90; data not shown). There was an insuffi-
cient number of trials in which authors reported data on in-
fectious outcomes and LOS in the low- and high-quality
trial categories to allow for these comparisons to be made.
Risk of publication bias across studies
Funnel plots for all outcomes were created to assess for
publication bias (data not shown). The test of asymmetry
Table 4 Relevant outcome parameters of included randomized studies of enteral glutamine supplementation in critically ill patien
Study Methods Intervention Mortality, n (%)a Infections, n (%)b Hospital sta (days) ICU LOS (days)




C. random: Yes >0.25 4/41 (9.8) 3/39 (7.7) 20/35 (57.1) 26/37 (70.2) 32.7 ± 17.1 33.0 ± 23.8 NA NA
ITT: No Altira Q (glutamine-enriched
formula) vs. isonitrogenous
control (added amino acids)Blinding: Yes
10 Same volume of feeding
received in both groups
Jones
et al. [25]
C. random: Yes 0.16 Hospital Hospital NA NA NA NA 11 (4–54) 16.5 (5–66)
ITT: No Protina Torre MP (Fresenius
Kabi, Bad Homburg,
Germany) + glutamine
(10–15 g/day nitrogen) vs.
isonitrogenous control
(11–14 g/day nitrogen)
10/26 (38.5) 9/24 (37.5)
Blinding: Yes ICU ICU
8 9/26 (35) 9/24 (38)
6 months 6 months
12/26 (46) 10/24 (42)
Brantley and
Pierce [26]
C. random: Not sure 0.50 0/31 (0.0) 0/41 (0.0) NA NA 19.5 ± 8.8 20.8 ± 11.5 11.4 11.1
ITT: No Glutamine-supplemented
enteral formula vs. standard
formula (isonitrogenous)
protein given 1.5 g/kg/day
Blinding: No
4





deaths)ITT: Yes Isocal (Nestlé Health Science,
Lutry, Switzerland) + glutamine
(66 g/day protein) vs.
isonitrogenous formula Isocal +
glycine (64 g/day protein)
24/179 (13) 23/184 (13)
Blinding: Yes ICU ICU
13 16/179 (9) 14/184 (8)
30 days 30 days
26/179 (15) 25/184 (14)
6 months 6 months
27/179 (15) 30/184 (16)
Hall et al. [27] C. random: Yes 0.27 7/76 (9) 6/78 (8) Sepsis Sepsis NA NA NA NA
Trauma
subgroup
ITT: Yes Isocal + glutamine (66 g/day
protein) vs. isonitrogenous
formula Isocal + glycine
(64 g/day protein)














Table 4 Relevant outcome parameters of included randomized studies of enteral glutamine supplementation in critically ill patients (Continued)
Garrel
et al. [28]




33 ± 17 (16)d 29 ± 17 (19)d NA NA
ITT: yes Sandosource (Nestlé Health
Science) + glutamine
(2.15 g/kg/day protein) vs.
Sandosource + amino acids
(isonitrogenous), 1.97 g/kg/day
protein





C. random: Yes 0.35 0/20 0/20 2/20 (10) 6/20 (30) 67 ± 4 (20) 73 ± 6 (20) NA NA
ITT: No Ensure (NutriDrinks, Perivale,








0.5 NA NA NA NA 46.6 ± 12.9 (25) 55.7 ± 17.4 (23) NA NA






Luo et al.e [31] C. random:
Not sure
0.32 ICU ICU NA NA NA NA 8.1 ± 0.4 (12) 6.9 ± 0.9 (9)
ITT: No Glutamine + IV saline + vs.
Nutren (Nestlé Health
Science) + 15 % Clinisol
(Baxter Healthcare, Deerfield,





28 days 28 days





0.5 (actual 0.4) IMPACT
(Nestlé Health Science) +
Glutasolve (Nestlé Health
Science) via NJ tube
(1.3 g/kg/day protein), bolus
with H2O vs. Impact + protein
supplements (isonitrogenous,
isocaloric) 0.85 g/kg/day protein









mixture + EN glutamine +
“regular” nutrition vs. enteral
isonitrogenous mixture +
“regular” nutrition





















Table 4 Relevant outcome parameters of included randomized studies of enteral glutamine supplementation in critically ill patients (Continued)
van Zanten
et al. [14]
C. random: Yes 0.28 (mean intake) glutamine,
omega-3, antioxidant-enriched






Hospital Hospital 80/152 (53) 78/149 (52) 38.2 ± 28.9 37.7 ± 27.5 23.7 ± 22.4 25.6 ± 24.0




12 30/152 (20) 29/149 (20)
28 days 28 days
31/152 (20) 25/149 (17)
6 months 6 months





C. random: Yes 0.28 (mean intake) glutamine,
omega-3, antioxidant-enriched




Hospital Hospital 32/55 (58) 36/54 (67) 44.4 ± 31.2 39.8 ± 25.3 31.3 ± 30.3 32.5 ± 27.5




12 5/55 (9) 6/54 (11)
28 days 28 days
4/55 (7) 2/54 (4)
6 months 6 months
8/55 (15) 59/54 (17)
C. random concealed randomization median (range), EN enteral nutrition, ITT intent to treat, IV intravenous, NA not applicable, NJ nasojejunal, TPN total parenteral nutrition
Data are presented as mean ± standard deviation or number (%), as appropriate
aHospital mortality unless otherwise stated
bNumber of patients with infections unless otherwise stated
cMedian and range hence not included in meta-analysis (Hall et al. 2003 [27]; p = not significant)
dSubgroup of patients, hence not included in the meta-analyses [28]










Fig. 1 Effects of enteral glutamine on hospital mortality. 95 % CI 95 % confidence interval, EN enteral nutrition, M-H Mantel-Haenszel
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including hospital mortality (p =0.18), infectious com-
plications (p =0.23), ICU LOS (p =0.25) and hospital LOS
(p =0.48).
Discussion
Our overall results reveal that enteral GLN does not
confer reductions in hospital mortality, with the excep-
tion of burn patients. We observed marked heterogen-
eity among the included studies, which are described indetail in Table 4. In our present analysis, we could not
find strong signals of publication bias effects on the pri-
mary outcome parameter, hospital mortality. Whether
this means that enteral GLN supplementation is safe for
critically ill patients should be interpreted with caution,
as previous analyses of parenteral GLN supplementation
have demonstrated divergent effects on mortality when
single-center studies were compared with multicenter
trials; in other words, the observed beneficial effects on
mortality were due to effects in single-center studies
Fig. 2 Effects of enteral glutamine on infectious complications. 95 % CI 95 % confidence interval, EN enteral nutrition, M-H Mantel-Haenszel
van Zanten et al. Critical Care  (2015) 19:294 Page 10 of 16[16, 66]. With respect to enteral GLN, our analysis
included only one multicenter study, and the results
of that study suggest increased harm [14].
Lack of effect on infectious morbidity
In contrast to earlier observations, we could not demon-
strate any beneficial effect of enteral GLN on infectiousFig. 3 Effects of enteral glutamine on ICU length of stay. 95 % CI 95 % con
intravenous, LOS, length of stay, SD standard deviationmorbidity. Only in burn patients was a small effect
seen; however, the number of patients is limited, which
precludes making strong recommendations. Recently, a
lack of effect of GLN administration to boost the innate
immune system response in trauma patients in the ICU
has been demonstrated. No increase in the expression
and/or functionality of Toll-like receptors, key receptorsfidence interval, EN enteral nutrition, ICU intensive care unit, IV
Fig. 4 Effects of enteral glutamine on hospital length of stay. 95 % CI 95 % confidence interval, EN enteral nutrition, IV intravenous, LOS, length of
stay, SD standard deviation
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supplementation [67]. Furthermore, protein intake
and infectious morbidity seem to be associated [68].
Therefore, the effects of GLN supplementation can be
studied adequately only in isonitrogenous intervention
studies.Reduction of hospital length of stay
Although a reduction in ICU LOS could not be demon-
strated, a reduction in hospital LOS of approximately
4.7 days (WMD −4.73, 95 % CI −8.56 to −0.90) persisted.
These results are in line with previously reported meta-
analyses [17, 53]. This signal is driven largely by three
studies of burn patients that, when aggregated, show a
reduction of more than 9 days in the hospital.Glutamine in burn patients
Burn patients may be a unique group of patients for
which GLN has clinically significant beneficial effects.
Low blood GLN levels have been observed in this pa-
tient population [28, 29], and the conditionally essential
hypothesis may apply to them. As noted in this review,
several small trials have shown benefits with regard
to blood infections [28] and LOS [29]. A similar ef-
fect was observed on Gram-negative blood infections in
two studies with different routes of GLN administration
[28, 69]. In a more recent study [33], researchers reported
a decrease in blood infection of identical magnitude.
Taken together, these observations strongly suggest
that GLN has a significant effect on blood infections
in burn patients. Decreased mortality was also found
in one study with enteral GLN administration [28],
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control group. Although this study was not powered
for testing an effect on mortality, the effect size observed
warrants a larger trial. Such a large-scale, multicenter
trial is currently underway, and stronger inferences
about the use of GLN in burn patients awaits the re-
sults [70].
Previous meta-analyses
In two meta-analyses of the initial randomized controlled
trials of enteral GLN supplementation, García-de-Lorenzo
et al. [53] and Jiang et al. [17] reported data on 17 and 7
studies, respectively. Although in the first meta-analysis
the number of studies that included various patient cat-
egories was larger than in our present analysis, the num-
ber of studies addressing the effects of enteral GLN in
critically ill patients was much lower. On the basis of their
results, although the doses given and the duration of ther-
apy varied widely depending on the pathologic condition,
García-de-Lorenzo et al. [53] recommended using GLN
intake of 20–30 g/day, early initiation of diet and mainten-
ance for at least 5 days (grade C recommendations) [53].
Jiang et al. [17] concluded that administration of GLN-
enhanced EN in patients with critical illness may reduce
nosocomial infection rates and shorten hospital LOS. Fur-
thermore, they recommended that studies be done with a
large sample size to verify the efficiency of GLN-enhanced
EN on lowering mortality in patients with critical illness.
Since the publication of the García-de-Lorenzo et al. and
Jiang et al. studies, another four studies have been pub-
lished, including the multinational, multicenter MetaPlus
study [14]. Incorporating data of these studies enabled us
to evaluate GLN in more than 1000 patients.
Safety concerns regarding glutamine supplementation
Two large multicenter trials, the REDOXS and the
MetaPlus trials [13, 14], have fueled the debate on the
safety and efficacy of GLN supplementation. Therefore,
we believe they need to be discussed in more detail. The
REDOXS trial was not included in our present analysis
for reasons of both enteral and parenteral GLN supple-
mentation [13].
The REDOXS trial was a factorial 2 × 2 randomized
trial conducted in 40 ICUs in North America and Europe.
A total of 1223 mechanically ventilated adult patients with
multiple organ dysfunction syndrome were randomized to
receive high doses of GLN, antioxidants, both or placebo
separate from artificial nutrition [13]. Total caloric intake
in both groups was about 900 kcal/day. The primary
analysis demonstrated no clinical benefit and identified a
trend toward increased mortality at 28 days (32.4 % vs.
27.2 %; adjusted odds ratio 1.28; 95 % CI 1.00–1.64;
p =0.049) and a significant increase in hospital and
6-month mortality among patients who received GLN.There was no effect of antioxidants on 28-day mortal-
ity [13].
The MetaPlus trial was conducted from February 2010
through April 2012. It included a 6-month follow-up
period in 14 ICUs in the Netherlands, Germany, France
and Belgium. A total of 301 adult patients who were ex-
pected to be ventilated and to require EN for more than
72 h were randomized to the intervention feed (enriched
with GLN and with antioxidants including selenium and
fish oils) or control feed within 48 h of ICU admission
and continued during ICU stay [14]. Consistent with
attempting to supplement patients because of presumed
nutrient deficiency, per 1500 ml, the enriched diet con-
tained 113 g of protein, of which 23 g were alanyl-
glutamine, and a total GLN content of 30 g; relatively
high amounts of antioxidants, including 285 μg of selen-
ium and an additional 7.5 g of fish oils. The control
group received an isocaloric standard high-protein EN
diet with similar amounts of proteins. There were no
statistically significant differences in new infections ac-
cording to the Centers for Disease Control and Prevention
(CDC) definitions: 53 % (95 % CI 44–61 %) in the
enriched group versus 52 % (95 % CI 44–61 %) in the con-
trol group (p =0.96). The study was designed to observe a
50 % relative reduction in incidence of new infections
based on an incidence of 25 % in the control arm (absolute
reduction of 12.5 %). The actual incidence of infections
was larger than estimated (53 % and 52 %). Therefore, the
study was not underpowered to detect differences in infec-
tions. Although the incidence of infections was higher
than estimated, no reduction of infectious morbidity was
observed. Secondary endpoints included mortality, Se-
quential Organ Failure Assessment scores, mechanical
ventilation duration, ICU and hospital LOS and sub-
types of infections according to CDC definitions. No
differences were observed in secondary endpoints, ex-
cept for a higher 6-month adjusted mortality rate in
the enriched group (hazard ratio 1.57, 95 % CI 1.03–
2.39; p =0.04) and an unadjusted higher mortality of
54 % in the medical subgroup (95 % CI 40–67 %)
versus 35 % (95 % CI 22–49 %) (p =0.04). Mortality
was a secondary endpoint in this study. However, we
cannot ignore the observation of increased mortality
just because it was a secondary endpoint. We have to
look at these secondary endpoints when considering
the safety of the intervention [71].
This meta-analysis does not suggest increased mortal-
ity with the use of enteral GLN supplementation. The
signals of harm in the REDOXS trial may be due to the
high dose of both enteral and parenteral GLN used, the
negative effects in patients with renal failure and the low
total caloric and protein intake, although these factors
remain speculative. In the MetaPlus study, harmful ef-
fects were observed in all patients with respect to the
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ical subgroup. The underlying mechanisms are still un-
clear, but data suggest that patients did worse if their
baseline GLN plasma levels were higher. Another ex-
planation could be that effects are due to the other
immune-modulating ingredients or to an interaction
among those.
Is the glutamine conditional deficiency hypothesis still
valid?
Overall, the benefits of enteral GLN supplementation seem
to be limited. This should lead to a reevaluation of the im-
portance and validity of the conditional deficiency hypoth-
esis of GLN in critically ill patients. Some have suggested
that low GLN plasma levels at ICU admission may be an
adaptive response and that supplementation could be
considered as a maladaptive response to this [72].
Several observations challenging the hypothesis have
been published recently. The frequency of patients with
low baseline plasma GLN levels is extremely variable
and is not consistent [31, 73, 74]. There is no association
of baseline plasma GLN and Acute Physiology and
Chronic Health Evaluation II score, as could be expected
when the severity of illness plays a role in conditional
deficiency [74]. Moreover, in general and septic ICU pa-
tients, high baseline plasma GLN (>930 μmol/L) was as-
sociated with increased mortality suggesting a U-shaped
association [74]. In addition, low baseline GLN levels
were not always associated with increased mortality [73].
Considering conditional deficiency, the GLN rate of
appearance from muscles to plasma is expected to be
around the maximum production rate, estimated by iso-
topic techniques at 40–80 g/24 h [75]. However, this
maximum muscle output could not be confirmed in a
tracer study in ICU patients. The endogenous produc-
tion of GLN in muscles and appearance in plasma were
related to severity of illness and did not diminish by sup-
plementation of GLN [76]. A trend toward higher mor-
tality was demonstrated in patients with higher baseline
GLN levels treated with GLN-enriched EN [14]. After
ICU discharge, patients showed normalized plasma GLN
levels not associated with long-term outcome. However,
patients with the highest plasma GLN on the ICU
discharge day showed a higher 1-year mortality [77].
Consequences of findings
Our observations do not support use of GLN in critically
ill patients; therefore, our present systematic review and
meta-analysis is important. Moreover, the recent large-
scale, multicenter trials (REDOXS and MetaPlus) show
no benefits, but instead indicate signals of increased
harm with respect to long-term mortality. All these ob-
servations and the concerns that have been published
should lead to a reevaluation of the validity of the GLNhypothesis in critically ill patients and probably also to
new recommendations for the practice guidelines devel-
oped by organizations such as the European Society for
Clinical Nutrition and Metabolism, the American Society
of Parenteral and Enteral Nutrition and the Canadian
Practice Guidelines Committee [15].
Strengths and weaknesses
The strengths of our meta-analysis include the use of
several methods to reduce bias: a comprehensive search
of the worldwide literature, including trials published in
languages other than English; duplicate data abstraction;
specific criteria for searching and analysis; and no in-
dustry funding. We also focused on clinically important
primary outcomes. Furthermore, we created funnel plots
for all primary and key secondary endpoints examined
to look for possible publication bias associated with
these endpoints.
In contrast, we are aware that our meta-analysis has
several limitations. Among these are the limited number
of larger trials [14, 27] and the small number of trials in-
cluded in certain subgroup analyses. Owing to the het-
erogeneity of the included studies, the internal validity
of our findings should be interpreted with caution. We
also unfortunately could not perform subgroup analysis
for all endpoints, owing to the limited number of trials
in which the particular endpoints were examined. An-
other potential weakness of our review is that the studies
included were published over the course of 2 decades.
This may be relevant, as in a time-sequential analysis,
Fadda and coworkers studied the effects of GLN supple-
mentation over time. They showed that only trials per-
formed before 2003 manifested a positive signal, whereas
more recent trials failed to demonstrate any positive
treatment effect [78]. Hence, it appears that only older,
small, single-center trials of intravenous GLN, when
meta-analyzed, showed a positive treatment effect.
Conclusions
In this comprehensive systematic review, we demon-
strate that enteral GLN supplementation given in con-
junction with EN support does not confer significant
reductions in hospital mortality among critically ill
patients, including trauma patients. However, it may
reduce hospital mortality in burn patients. No effects on
infectious morbidity or ICU LOS were observed. Hos-
pital LOS was significantly reduced in critically ill and
burn patients but not in trauma patients. However, the
results of our meta-analysis are based mainly on smaller,
single-center studies, and two recent multicenter trials
have suggested potential harm of GLN. Therefore, en-
teral GLN supplementation cannot be recommended for
critically ill patients. In burn patients, larger studies are
warranted, as our observations of a beneficial effect are
van Zanten et al. Critical Care  (2015) 19:294 Page 14 of 16based on a small number of patients. Such a trial is cur-
rently underway worldwide (citation: see Clinical trials.
gov ID #NCT00985205).
Key messages
 In critically ill patients, including trauma patients,
supplemental enteral GLN does not decrease
hospital mortality, infectious morbidity or ICU LOS.
 Supplemental enteral GLN does significantly reduce
hospital mortality in burn patients; however, the
relevant studies were small.
 Supplemental enteral GLN significantly shortens
hospital LOS in critically ill and burn patients but
not in critically ill trauma patients.
 Supplemental enteral GLN should not be given to
critically ill patients or trauma patients, as its
benefits are limited.
 Moreover, results are based mainly on single-center
studies, and two recent multicenter trials have
suggested potential harm of GLN.
 More data on enteral GLN supplementation are
warranted in burn patients as present observations
of a benefit are based on a small number of patients.
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